Dashboard
Manage Tickers

FULC Fulcrum Therapeutics, Inc.

Nasdaq fulcrumtx.com


$ 7.80 $ -0.54 (-6.48 %)    

Wednesday, 05-Nov-2025 14:28:44 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 626.20 $ 7.73 (1.25 %)
DIA $ 473.80 $ 2.93 (0.62 %)
SPY $ 680.36 $ 5.32 (0.79 %)
TLT $ 88.96 $ -0.55 (-0.61 %)
GLD $ 366.54 $ 0.09 (0.02 %)
$ 8.37
$ 8.15
$ 7.81 x 230
$ 7.82 x 46
$ 7.71 - $ 8.32
$ 2.32 - $ 10.11
717,358
na
452.97M
$ 1.75
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 10-29-2025 09-30-2025 10-Q
2 07-29-2025 06-30-2025 10-Q
3 05-01-2025 03-31-2025 10-Q
4 02-25-2025 12-31-2024 10-K
5 11-13-2024 09-30-2024 10-Q
6 07-31-2024 06-30-2024 10-Q
7 05-13-2024 03-31-2024 10-Q
8 02-27-2024 12-31-2023 10-K
9 11-07-2023 09-30-2023 10-Q
10 08-03-2023 06-30-2023 10-Q
11 05-15-2023 03-31-2023 10-Q
12 03-09-2023 12-31-2022 10-K
13 11-08-2022 09-30-2022 10-Q
14 08-11-2022 06-30-2022 10-Q
15 05-09-2022 03-31-2022 10-Q
16 03-03-2022 12-31-2021 10-K
17 11-04-2021 09-30-2021 10-Q
18 08-10-2021 06-30-2021 10-Q
19 05-06-2021 03-31-2021 10-Q
20 03-04-2021 12-31-2020 10-K
21 11-10-2020 09-30-2020 10-Q
22 08-11-2020 06-30-2020 10-Q
23 05-13-2020 03-31-2020 10-Q
24 03-05-2020 12-31-2019 10-K
25 11-14-2019 09-30-2019 10-Q
26 08-26-2019 06-30-2019 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

fulcrum-therapeutics-to-present-new-data-from-the-phase-1b-pioneer-trial-of-pociredir-in-sickle-cell-disease-scd-will-be-presented-at-the-67th-american-society-of-hematology-annual-meeting
Fulcrum Therapeutics To Present New Data F...
11/03/2025 21:48:34

Fulcrum Therapeutics, Inc.® (the "Company") (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on develo...

Core News & Articles
10 Health Care Stocks Whale Activity In To...
11/03/2025 17:35:20

rbc-capital-maintains-sector-perform-on-fulcrum-therapeutics-raises-price-target-to-7
RBC Capital Maintains Sector Perform on Fu...
10/30/2025 14:58:53

RBC Capital analyst Luca Issi maintains Fulcrum Therapeutics (NASDAQ:FULC) with a Sector Perform and raises the price target...

piper-sandler-reiterates-overweight-on-fulcrum-therapeutics-raises-price-target-to-16
Piper Sandler Reiterates Overweight on Ful...
10/30/2025 13:37:00

Piper Sandler analyst Edward Tenthoff reiterates Fulcrum Therapeutics (NASDAQ:FULC) with a Overweight and raises the price t...

earnings-scheduled-for-october-29-2025
Earnings Scheduled For October 29, 2025
10/29/2025 11:11:56

fulcrum-therapeutics-q3-eps-031-misses-029-estimate-cash-2006m
Fulcrum Therapeutics Q3 EPS $(0.31) Misses...
10/29/2025 11:02:49

Fulcrum Therapeutics (NASDAQ:FULC) reported quarterly losses of $(0.31) per share which missed the analyst consensus estimate o...

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
10/23/2025 21:06:21

hc-wainwright--co-reiterates-buy-on-fulcrum-therapeutics-maintains-12-price-target
HC Wainwright & Co. Reiterates Buy on Fulc...
10/20/2025 11:56:10

HC Wainwright & Co. analyst Andrew S. Fein reiterates Fulcrum Therapeutics (NASDAQ:FULC) with a Buy and maintains $12 pr...

fulcrum-therapeutics-to-present-preclinical-data-on-ftx-6274-for-advanced-prostate-cancer-at-esmo-2025
Fulcrum Therapeutics to Present Preclinica...
10/14/2025 11:11:27

Fulcrum Therapeutics, Inc.® (Fulcrum) (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small mol...

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
09/25/2025 21:06:11

Gainers Galecto (NASDAQ: GLTO) stock rose 21.6% to $5.41 during Thursday's after-market session. The market value of their...

rbc-capital-maintains-sector-perform-on-fulcrum-therapeutics-raises-price-target-to-5
RBC Capital Maintains Sector Perform on Fu...
07/30/2025 14:26:59

RBC Capital analyst Luca Issi maintains Fulcrum Therapeutics (NASDAQ:FULC) with a Sector Perform and raises the price target...

avis-budget-group-posts-downbeat-earnings-joins-sofi-technologies-seagate-and-other-big-stocks-moving-lower-in-wednesdays-pre-market-session
Avis Budget Group Posts Downbeat Earnings,...
07/30/2025 12:05:06

hc-wainwright--co-upgrades-fulcrum-therapeutics-to-buy-raises-price-target-to-12
HC Wainwright & Co. Upgrades Fulcrum Thera...
07/29/2025 15:34:05

HC Wainwright & Co. analyst Andrew Fein upgrades Fulcrum Therapeutics (NASDAQ:FULC) from Neutral to Buy and raises the p...

whirlpool-posts-downbeat-earnings-joins-harmonic-stanley-black--decker-and-other-big-stocks-moving-lower-in-tuesdays-pre-market-session
Whirlpool Posts Downbeat Earnings, Joins H...
07/29/2025 12:20:41

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
07/29/2025 12:07:53

fulcrum-therapeutics-q2-2025-eps-028-beats-029-estimate-ended-q2-with-2141m-in-cash-cash-equivalents-and-marketable-securities-cash-runway-into-2028
Fulcrum Therapeutics Q2 2025 EPS $(0.28) B...
07/29/2025 10:51:02

fulcrum-therapeutics-reports-results-from-12-mg-dose-cohort-of-phase-1b-pioneer-trial-of-pociredir-in-sickle-cell-disease
Fulcrum Therapeutics Reports Results From ...
07/29/2025 10:47:53

― Robust and clinically meaningful absolute mean fetal hemoglobin (HbF) induction of 8.6% from baseline at 12 weeks of treatmen...

why-celestica-shares-are-trading-higher-by-around-12-here-are-20-stocks-moving-premarket
Why Celestica Shares Are Trading Higher By...
07/29/2025 10:46:00

fulcrum-therapeutics-to-present-topline-results-from-12-mg-dose-cohort-of-phase-1b-pioneer-trial-of-pociredir-in-sickle-cell-disease
Fulcrum Therapeutics To Present Topline Re...
07/28/2025 20:02:21

Fulcrum Therapeutics, Inc.® (Fulcrum) (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small mol...

piper-sandler-maintains-overweight-on-fulcrum-therapeutics-raises-price-target-to-9
Piper Sandler Maintains Overweight on Fulc...
05/29/2025 16:54:46

Piper Sandler analyst Edward Tenthoff maintains Fulcrum Therapeutics (NASDAQ:FULC) with a Overweight and raises the price ta...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION